ArticleRheumatology (Oxford, England)2024
Lung imaging patterns in connective tissue disease-associated interstitial lung disease impact prognosis and immunosuppression response.
Article in Rheumatology (Oxford, England), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- High-resolution computed tomography assessment of connective tissue disease-associated interstitial lung disease: Advances in diagnosis and prognostic evaluation.World journal of radiology · 2026Review
- Diagnostic significance of HRCT imaging features in idiopathic inflammatory myopathy-associated interstitial lung disease.BMC pulmonary medicine · 2026Article
- Tumor markers in rheumatoid arthritis -associated interstitial lung disease: a systematic review and meta-analysis.BMC rheumatology · 2026Article
- Spectrum of autoantibodies and other serological parameters in connective tissue disease-associated interstitial lung disease patients.Frontiers in medicine · 2026Article
- Clinical significance of radiological usual interstitial pneumonia pattern in primary Sjögren syndrome-associated interstitial lung disease.Frontiers in immunology · 2026Article
- Cluster analysis and risk prediction model construction for antisynthase syndrome-associated interstitial lung disease based on clinical, imaging, and antibody characteristics.Frontiers in medicine · 2026Article
- Interstitial lung disease in systemic autoimmune rheumatic diseases: radiologic and histologic correlations.Rheumatology advances in practice · 2026Article
- Pulmonary cystic destruction in systemic sclerosis and antisynthetase syndrome associated non-specific interstitial pneumonitis: a case series of a novel radiological phenotype.Rheumatology advances in practice · 2026Article
- Biomarkers on Fibrotic Lung Diseases Associated with Usual Interstitial Pneumonia.International journal of medical sciences · 2026Review
- The importance of considering progression speed in systemic sclerosis-associated interstitial lung diseases: application of 2022 and 2024 clinical practice guidelines for progressive pulmonary fibrosis, a retrospective cohort study.Respiratory research · 2025Article
- Clinical, radiologic, and serologic predictors of rheumatic disease in interstitial lung disease patients.Clinical rheumatology · 2025Article
- Serum inflammatory markers as predictors of therapeutic response in non-idiopathic pulmonary fibrosis fibrotic interstitial lung disease: a retrospective cohort analysis.BMC pulmonary medicine · 2025Article
- Extent of lung fibrosis is of greater prognostic importance than HRCT pattern in patients with progressive pulmonary fibrosis: data from the ILD-PRO registry.Respiratory research · 2025Article
- Article
- Breaking the cycle: should we target inflammation, fibrosis, or both?Frontiers in immunology · 2025Review
- Interstitial Lung Disease Phenotypes and Predictive Risk Factors in Primary Sjögren's Syndrome.Journal of clinical medicine · 2024Article
- Potential of phosphodiesterase 4B inhibition in the treatment of progressive pulmonary fibrosis.Therapeutic advances in respiratory diseaseReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
41 authors.
Funding
Abstract
objectivesInterstitial lung disease (ILD) in CTDs has highly variable morphology. We aimed to identify imaging features and their impact on ILD progression, mortality, and immunosuppression response.
methodsPatients with CTD-ILD had high-resolution chest CT (HRCT) reviewed by expert radiologists blinded to clinical data for overall imaging pattern [usual interstitial pneumonia (UIP); non-specific interstitial pneumonia (NSIP); organizing pneumonia (OP); fibrotic hypersensitivity pneumonitis (fHP); and other]. Transplant-free survival and change in percent-predicted forced vital capacity (FVC) were compared using Cox and linear mixed-effects models adjusted for age, sex, smoking, and baseline FVC. FVC decline after immunosuppression was compared with pre-treatment.
resultsAmong 645 CTD-ILD patients, the most frequent CTDs were SSc (n = 215), RA (n = 127), and inflammatory myopathies (n = 100). NSIP was the most common pattern (54%), followed by UIP (20%), fHP (9%), and OP (5%). Compared with the case for patients with UIP, FVC decline was slower in patients with NSIP (by 1.1%/year, 95% CI 0.2, 1.9) or OP (by 3.5%/year, 95% CI 2.0, 4.9), and mortality was lower in patients with NSIP [hazard ratio (HR) 0.65, 95% CI 0.45, 0.93] or OP (HR 0.18, 95% CI 0.05, 0.57), but higher in fHP (HR 1.58, 95% CI 1.01, 2.40). The extent of fibrosis also predicted FVC decline and mortality. After immunosuppression, FVC decline was slower compared with pre-treatment in NSIP (by 2.1%/year, 95% CI 1.4, 2.8), with no change for UIP or fHP.
conclusionMultiple radiologic patterns are possible in CTD-ILD, including a fHP pattern. NSIP and OP were associated with better outcomes and response to immunosuppression, while fHP had worse survival compared with UIP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.